Should you stop taking OTC alli after the FDA added a kidney injury warning?
FDA added a new kidney injury and kidney stone warning to OTC alli on June 10, 2026. This was a label change, not a recall, but some users should check with a clinician before using it.
On June 10, 2026, FDA approved labeling changes for the over-the-counter weight-loss drug alli, the 60 mg orlistat product sold without a prescription. The update adds stronger warning language about rare kidney stones and acute kidney injury.
The practical takeaway is that this was a labeling change, not a recall. For many people, the next step is not panic but checking the updated Drug Facts label, knowing the symptoms FDA lists, and asking a clinician or pharmacist whether the product still makes sense for you.
What changed on the label
According to FDA, the updated label tells consumers to ask a health care provider before using alli if they have ever had kidney disease or kidney stones. It also tells consumers to stop using alli and contact a doctor if they develop symptoms of kidney injury or kidney stones.
FDA lists these symptoms specifically: back or groin pain, painful urination, blood in the urine, feet and leg swelling, or less frequent urination.
That language matters because many people buy over-the-counter products without first talking to a clinician. A stronger warning on the box is meant to help people recognize a rare but serious problem earlier.
This is a label update, not a recall
The June 10 action did not remove alli from the market. FDA changed the warning language so kidney risk is described more clearly for consumers.
In other words, this is a safety communication about labeling, not a notice that everyone should automatically throw the product away.
What alli is used for
alli contains orlistat, a lipase inhibitor. It works by blocking absorption of some of the fat eaten in meals. FDA says it is approved for weight loss in overweight adults age 18 and older when used with a reduced-calorie, low-fat diet. MedlinePlus also describes it as part of a broader weight-loss plan that includes diet and exercise.
alli is the only FDA-approved over-the-counter weight-loss aid in the United States.
Who may need extra caution
The clearest higher-risk groups in the new warning are people with a history of kidney disease or kidney stones. FDA now says those consumers should ask a health care provider before using alli.
Kidney-disease context matters for another reason: CDC lists diabetes, high blood pressure, and obesity as risk factors for chronic kidney disease. Some people may have kidney disease and not know it yet, since early chronic kidney disease often causes few or no symptoms.
FDA’s own review also found that several reported cases involved people who had other possible reasons for kidney problems, including obesity, diabetes, high blood pressure, or a prior history of kidney disease or kidney stones.
What FDA found
FDA reviewed postmarketing reports and medical literature covering alli use from its 2007 approval through the end of 2023. The agency identified 12 cases of kidney complications tied to alli use in its review. Eight patients were hospitalized, five required dialysis, and some reports described improvement after the event.
At the same time, FDA said the case reports had important limits. Not every side effect gets reported, some reports were missing clinical details, and several patients had other kidney risk factors. That means the reports support concern, but they do not answer every question about exactly who will develop a problem or how often it happens.
What older research suggests, and what it cannot prove
An older observational study published in JAMA Internal Medicine found more acute kidney injury events in the year after people started orlistat than in the year before they started it. In that analysis of 953 patients, 18 acute kidney injury events occurred after starting the drug compared with 5 before.
But that study does not prove that orlistat directly caused the injuries. It was not a randomized trial, it relied on observational data, and the researchers could not confirm the suspected oxalate-related kidney mechanism in every case. The study is useful background, but it should be read as a signal, not final proof.
Should you stop taking alli?
If you are taking alli and do not have symptoms, the FDA action does not mean there has been a recall. It does mean you should read the updated label carefully and rethink the product if you have a history of kidney disease or kidney stones.
If you develop the symptoms FDA lists, the agency says to stop using alli and contact a health care provider. If symptoms feel severe, worsen quickly, or you are urinating much less than usual, seek urgent medical care.
Do not use a safety headline alone as a reason to start, stop, or switch a weight-loss medicine on your own if you are unsure how it applies to you. A clinician or pharmacist can help review your kidney history, your other conditions, and any medicines or supplements you take.
What readers can do now
- Check the Drug Facts label on any alli package you have at home.
- Ask a clinician or pharmacist before using alli if you have ever had kidney disease or kidney stones.
- Watch for the symptoms FDA names: back or groin pain, painful urination, blood in the urine, feet and leg swelling, or less frequent urination.
- Bring a full list of your medicines and supplements to any discussion about weight-loss treatment, since orlistat can have other precautions and interactions.
- If you had a side effect while using alli, consider reporting it through FDA MedWatch.
For most readers, the bottom line is simple: this is a safety-label update meant to help people catch a rare but serious problem earlier. The key question is not whether alli was recalled. It is whether your personal kidney risk makes the product a poor fit for you now.
Sources
Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.
This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.
